LRIG2 (leucine rich repeats and immunoglobulin like domains 2) encodes a single-pass transmembrane glycoprotein located on chromosome 1 with structural similarity to LRIG1 1. The protein contains 15 leucine-rich repeats, three immunoglobulin-like domains, and undergoes N-linked glycosylation, localizing to both cell surface and cytoplasm 1. LRIG2 exhibits widespread tissue expression with highest levels in skin, uterus, ovary, kidney, and brain 1. Functionally, LRIG2 plays critical roles in peripheral nerve patterning within the urinary tract, as mutations cause urofacial syndrome 2, characterized by functional bladder outlet obstruction due to altered bladder innervation rather than anatomical blockage 2. In cancer contexts, LRIG2 generally functions as an oncogene, promoting tumor progression through multiple mechanisms including modulation of immune evasion via CD47-SIRPα signaling in glioblastoma 3, resistance to EGFR inhibitors through GAS6/AXL/SRC pathway activation 4, and regulation of cell proliferation and apoptosis in osteosarcoma 5. Unlike LRIG1 and LRIG3, LRIG2 expression is typically associated with poor cancer prognosis across multiple tumor types 6. Additionally, LRIG2 can influence both local and distant gene expression through chr1 interactions mediated by retrotransposon insertion polymorphisms 7.